As BioMarin Stumbles, Sanofi Gets Breakthrough Status For Hemlibra Challenger

US Filing Expected Shortly

 
• By Andrew McConaghie
  
Sanofi_Berlin
Sanofi has made rare blood disorders one of its targeted key growth drivers. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip